Home » Stocks » ARDX

Ardelyx, Inc. (ARDX)

Stock Price: $6.67 USD 0.01 (0.15%)
Updated Mar 5, 2021 4:00 PM EST - Market closed
After-hours: $6.74 +0.07 (1.05%) Mar 5, 5:57 PM
Market Cap 601.96M
Revenue (ttm) 8.01M
Net Income (ttm) -85.23M
Shares Out 89.37M
EPS (ttm) -1.01
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day March 5
Last Price $6.67
Previous Close $6.66
Change ($) 0.01
Change (%) 0.15%
Day's Open 6.70
Day's Range 6.08 - 6.80
Day's Volume 1,581,396
52-Week Range 4.22 - 8.33

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
GlobeNewsWire - 5 days ago

MONTREAL, March 01, 2021 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD), (“Knight”) a pan-American (ex-USA) specialty pharmaceutical company, announced today the Canadian commercial a...

Zacks Investment Research - 1 week ago

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

PRNewsWire - 2 weeks ago

FREMONT, Calif., Feb. 17, 2021 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatment for peop...

Benzinga - 2 months ago

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...

Other stocks mentioned: CAR, CNNE, MPLN, SBTX, SEER
PRNewsWire - 4 months ago

FREMONT, Calif., Nov. 6, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidn...

Zacks Investment Research - 4 months ago

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 4 months ago

I last wrote about Ardelyx as the company was close to submitting its tenapanor NDA and the stock was trading for over $8. Since that time, Ardelyx had gotten its NDA accepted with an April 29...

PRNewsWire - 4 months ago

FREMONT, Calif. and TOKYO, Oct. 22, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company developing targeted, first-in-class medicines to improve the lives of patient...

PRNewsWire - 4 months ago

FREMONT, Calif., Oct. 12, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kid...

24/7 Wall Street - 5 months ago

Ardelyx Inc. (NASDAQ: ARDX) shares dipped on Tuesday after the firm posted a win with the U.S.

Seeking Alpha - 6 months ago

Giving The 'Thumbs Up' On Ardelyx

Zacks Investment Research - 7 months ago

Ardelyx (ARDX) delivered earnings and revenue surprises of -3.70% and 63.06%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

PRNewsWire - 7 months ago

FREMONT, Calif., Aug. 3, 2020 /PRNewswire/ -- Ardelyx, Inc.

Zacks Investment Research - 7 months ago

Ardelyx (ARDX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

PRNewsWire - 8 months ago

FREMONT, Calif., June 9, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatme...

PRNewsWire - 8 months ago

FREMONT, Calif., June 8, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatme...

Seeking Alpha - 9 months ago

Ardelyx: Sales Estimates For Tenapanor Suggest Upside In The Stock

PRNewsWire - 9 months ago

FREMONT, Calif., May 21, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatme...

PRNewsWire - 9 months ago

FREMONT, Calif., May 18, 2020 /PRNewswire/ -- Ardelyx, Inc. (Nasdaq: ARDX), a specialized biopharmaceutical company focused on developing innovative first-in-class medicines to improve treatme...

Zacks Investment Research - 9 months ago

As of late, it has definitely been a great time to be an investor Ardelyx

Zacks Investment Research - 9 months ago

Ardelyx (ARDX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).

Zacks Investment Research - 10 months ago

Does Ardelyx (ARDX) have what it takes to be a top stock pick for momentum investors? Let's find out.

Zacks Investment Research - 1 year ago

Ardelyx (ARDX) delivered earnings and revenue surprises of 17.65% and 221.43%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Seeking Alpha - 1 year ago

Ardelyx: A Promising Cardiorenal Small Cap Pick For 2020

The Motley Fool - 1 year ago

With its first FDA approval in hand, a second, more lucrative indication looms on the horizon.

The Motley Fool - 1 year ago

Investors reacted positively to the drugmaker's late-stage clinical results.

Seeking Alpha - 1 year ago

Ardelyx's Tenapanor Is A Long-Needed Alternative For A Cardiorenal Disease Complication

The Motley Fool - 1 year ago

Investors appear to be taking profits off the table after the biotech announced a key FDA approval.

Zacks Investment Research - 1 year ago

Ardelyx (ARDX) gets first-ever FDA approval for its pipeline candidate, tenapanor, as a treatment for irritable bowel syndrome with constipation in adults. It will be available under the trade...

24/7 Wall Street - 1 year ago

Ardelyx Inc. (NASDAQ: ARDX) shares dropped sharply on Friday after the firm announced that the U.S. Food and Drug Administration (FDA) has approved its treatment of irritable bowel syndrome wi...

Zacks Investment Research - 1 year ago

Ardelyx (ARDX) saw a big move last session, as its shares jumped more than 8% on the day, amid huge volumes.

Seeking Alpha - 1 year ago

Ardelyx announced positive results from its first phase 3 study for CKD patients on dialysis and hyperphosphatemia using its drug tenapanor.

Benzinga - 1 year ago

Shares of the thinly traded, micro-cap biotech Ardelyx Inc (NASDAQ: ARDX) have risen over 200% year-to-date.

The Motley Fool - 1 year ago

The clinical-stage biotech's stock gave back about half of Tuesday's big gain in Wednesday morning trading.

Zacks Investment Research - 1 year ago

Ardelyx's (ARDX) lead pipeline candidate, tenapanor, meets primary endpoint in a pivotal phase III study.

Benzinga - 1 year ago

Shares of Ardelyx Inc (NASDAQ: ARDX) were advancing strongly on above-average volume Tuesday following a clinical trial readout from the company.

The Motley Fool - 1 year ago

Shares jump after the clinical-stage biotech reports encouraging results from an important late-stage trial.

Seeking Alpha - 1 year ago

Ardelyx drug, tenapranor, has been studied in two underserved markets that both exceed $1 billion in US revenues, namely IBS-C and hyperphosphatemia in dialysis patients.

Zacks Investment Research - 1 year ago

Ardelyx (ARDX) delivered earnings and revenue surprises of -5.13% and -97.00%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Ardelyx (ARDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Zacks Investment Research - 1 year ago

Ardelyx (ARDX) delivered earnings and revenue surprises of -10.53% and -100.00%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research - 1 year ago

Ardelyx (ARDX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

About ARDX

Ardelyx, a biopharmaceutical company, develops and sells medicines for the treatment of cardiorenal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase 3 clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase 3 clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patient... [Read more...]

Industry
Biotechnology
IPO Date
Jun 19, 2014
CEO
Michael Raab
Employees
88
Stock Exchange
NASDAQ
Ticker Symbol
ARDX
Full Company Profile

Financial Performance

In 2019, Ardelyx's revenue was $5.28 million, an increase of 102.57% compared to the previous year's $2.61 million. Losses were -$94.94 million, 3.99% more than in 2018.

Financial Statements

Analyst Forecasts

According to 7 analysts, the average rating for Ardelyx stock is "Strong Buy." The 12-month stock price forecast is 14.00, which is an increase of 109.90% from the latest price.

Price Target
$14.00
(109.90% upside)
Analyst Consensus: Strong Buy